money_istock-504240346_jansucko
jansucko / iStockphoto.com
29 June 2018Europe

Advent agrees to buy Sanofi’s European generics unit

Private equity investor Advent International has agreed to acquire France-based Sanofi's European generics business Zentiva.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Europe
19 April 2018   France-based Sanofi has confirmed it is in negotiations to sell its European generics business Zentiva for €1.9 billion ($2.4 billion) to private equity firm Advent International.
Asia-Pacific
5 July 2018   France-based Sanofi has announced plans to launch a research and development hub in China to focus on digitalisation and big data analysis.

More on this story

Europe
19 April 2018   France-based Sanofi has confirmed it is in negotiations to sell its European generics business Zentiva for €1.9 billion ($2.4 billion) to private equity firm Advent International.
Asia-Pacific
5 July 2018   France-based Sanofi has announced plans to launch a research and development hub in China to focus on digitalisation and big data analysis.

More on this story

Europe
19 April 2018   France-based Sanofi has confirmed it is in negotiations to sell its European generics business Zentiva for €1.9 billion ($2.4 billion) to private equity firm Advent International.
Asia-Pacific
5 July 2018   France-based Sanofi has announced plans to launch a research and development hub in China to focus on digitalisation and big data analysis.